Sonntag, 18. April 2021
Navigation öffnen
Anzeige:
Imfinzi NSCLC
Imfinzi NSCLC
JOURNAL ONKOLOGIE – STUDIE
NEOMUN

Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer

Rekrutierend

NCT-Nummer:
NCT03197467

Studienbeginn:
Juni 2018

Letztes Update:
14.04.2021

Wirkstoff:
Pembrolizumab

Indikation (Clinical Trials):
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
Phase 2

Sponsor:
AIO-Studien-gGmbH

Collaborator:
Merck Sharp & Dohme Corp.

Studienleiter

Martin E. Eichhorn, PD Dr. med.
Principal Investigator
University Hospital Heidelberg

Kontakt

Studienlocations
(1 von 1)

Universitätsklinikum Heidelberg
69126 Heidelberg
(Baden-Württemberg)
GermanyRekrutierend» Google-Maps
Ansprechpartner:
Martin E. Eichhorn, PD Dr. med.
Phone: 06221396
Phone (ext.): 8107
E-Mail: Martin.Eichhorn@med.uni-heidelberg.de
» Ansprechpartner anzeigen

Studien-Informationen

Detailed Description:

The study is designed as an open-label, single arm, prospective, monocenter, phase II study

of pembrolizumab in a neoadjuvant setting in patients with resectable NSCLC stage II/IIIA

suitable for curative intent surgery, taking place in Germany. Planned sample size is N=30.

Investigational drug is Pembrolizumab at fixed dose, given 200 mg q3w i.v. for 2 cycles.

After completion of immunotherapy lobectomy/ bilobectomy with curative intent is scheduled.

Primary objectives are to assess feasibility and safety of a neoadjuvant application of

pembrolizumab and to assess antitumor activity of pembrolizumab with regard to clinical and

pathologic tumor response. Secondary objective is to assess the impact of neoadjuvant

pembrolizumab on patient disease free and overall survival. Exploratory objective is o

explore potential predictive biomarkers for pembrolizumab efficacy (immune cell imaging).

Ein-/Ausschlusskriterien

Inclusion Criteria:

1. Cooperation and willingness to complete all aspects of the study

2. Signed and dated written informed consent must be given prior to study inclusion

3. Histological or cytological confirmed NSCLC

4. Clinical stage II-IIIA according to the TNM classification, 7th edition:

stage IIIa: T1/T2 N2 (IIIa1-3 Robinson classification)

5. Adequate disease staging by PET/CT and brain MRI

6. At least 1 measurable lesion according to RECIST 1.1

7. Age ≥ 18 years

8. ECOG performance status 0 - 1

9. Female subjects of childbearing potential must be willing to use an adequate method of

contraception for the course of the study through 120 days after the last dose of

study medication. Note: Abstinence is acceptable if this is the usual lifestyle and

preferred contraception for the subject. Female subject of childbearing potential

should have a negative urine or serum pregnancy within 72 hours prior to receiving the

first dose of study medication. If the urine test is positive or cannot be confirmed

as negative, a serum pregnancy test will be required.

10. Male subjects of childbearing potential must agree to use an adequate method of

contraception, starting with the first dose of study therapy through 120 days after

the last dose of study therapy. Note: Abstinence is acceptable if this is the usual

lifestyle and preferred contraception for the subject

11. Adequate bone marrow function, liver and renal function:

1. Absolute neutrophil count ≥ 1.5 x 109/L

2. Thrombocytes ≥ 100 x 109/L

3. Hemoglobin ≥ 9 g/dL without transfusion or EPO dependency (within 7 days of

assessment)

4. INR < 1.4 ULN and PTT < 40 seconds during the last 7 days before therapy

5. Bilirubin < 1.5 x upper limit of normal

6. AST (GOT) and ALT (GPT) < 2.5 x ULN

7. Albumin >2.5 mg/dL

8. Serum creatinine OR Measured or calculated creatinine clearance (GFR can also be

used in place of creatinine or CrCl): ≤1.5 X upper limit of normal (ULN) OR ≥60

mL/min for subject with creatinine levels > 1.5 X institutional ULN

12. Adequate lung and cardiac function for intended lung resection according to German S3

guideline

Exclusion Criteria:

1. Anticancer treatment during the last 30 days prior to start of treatment, including

systemic therapy, radiotherapy or major surgery

2. Participation in a clinical trial within the last 30 days prior to study treatment

3. History of allogeneic tissue/solid organ transplant

4. Has a history of (non-infectious) pneumonitis that required steroids or current

pneumonitis.

5. Evidence of interstitial lung disease.

6. cT4 tumor

7. Symptomatic acute cardiovascular or cerebrovascular disease

8. Known active HBV, HCV or HIV infection

9. Has any other active infection requiring systemic therapy.

10. Patients with active tuberculosis

11. Prior therapy with an anti-Programmed cell death protein 1 (anti-PD-1), anti-PD-L1,

anti-Programmed cell death-ligand 2 (anti-PD-L2), anti-CD137 (4-1BB ligand, a member

of the Tumor Necrosis Factor Receptor [TNFR] family), or anti-Cytotoxic

T-lymphocyte-associated antigen-4 (anti-CTLA-4) antibody (including ipilimumab or any

other antibody or drug specifically targeting T-cell co-stimulation or checkpoint

pathways)

12. A diagnosis of immunodeficiency or patient is receiving chronic systemic steroid

therapy or any other form of immunosuppressive therapy within 7 days prior to the

first dose of trial treatment.

13. Patient has had a prior monoclonal antibody within 4 weeks prior to study Day 1

14. Patient has had prior chemotherapy, targeted small molecule therapy, or radiation

therapy in history.

15. Has an active autoimmune disease requiring systemic treatment within the past 3 months

or a documented history of clinically severe autoimmune disease, or a syndrome that

requires systemic steroids or immunosuppressive agents. Subjects with vitiligo or

resolved childhood asthma/atopy would be an exception to this rule. Subjects that

require intermittent use of bronchodilators or local steroid injections would not be

excluded from the study. Subjects with hypothyroidism stable on hormone replacement or

Sjorgen's syndrome will not be excluded from the study.

16. Has received a live vaccine within 30 days prior to the first dose of trial treatment.

[Seasonal influenza vaccines for injection are generally inactivated flu vaccines and

are allowed; however intranasal influenza vaccines are live attenuated vaccines, and

are not allowed.]

17. Has known hypersensitivity to pembrolizumab or any of the constituents of the product.

18. Other active malignancy requiring treatment Exceptions include basal cell carcinoma of

the skin or squamous cell carcinoma of the skin that has undergone potentially

curative therapy or in situ cervical cancer.

19. Lactating or pregnant women, women of child-bearing potential who do not agree to the

usage of highly effective contraception methods (allowed methods of contraception,

meaning methods with a rate of failure of less than 1% per year are implants,

injectable contraceptives, combined oral contraceptives, intrauterine pessars (only

hormonal devices), sexual abstinence or vasectomy of the partner). Women of

childbearing potential must have a negative pregnancy test (serum β-hCG) at Screening.

20. Any psychiatric illness that would affect the patient's ability to understand the

demands of the clinical trial

21. Patient has already been recruited in this trial

22. Patient who has been incarcerated or involuntarily institutionalized by court order or

by the authorities § 40 Abs. 1 S. 3 Nr. 4 AMG.

23. Patients who are unable to consent because they do not understand the nature,

significance and implications of the clinical trial and therefore cannot form a

rational intention in the light of the facts [§ 40 Abs. 1 S. 3 Nr. 3a AMG].

Studien-Rationale

Primary outcome:

1. frequency and severity of adverse events including periand post-operative complications (Time Frame - 46 month):
grade 2-4 AEs according to NCI-CTCAE V4.03

2. number of patients treated in compliance with protocol (Time Frame - 46 month)

3. Tumor response evaluation - Clinical response (Time Frame - 46 month):
response rates (Δ tumor size) according to RECIST 1.1 criteria response rates (Δ lymph node size) according to RECIST 1.1 criteria Δ PET-activity (standardized uptake value [SUV])

4. Tumor response evaluation - Pathologic response (Time Frame - 46 month):
Pathologic regression grading according to Junker criteria

Secondary outcome:

1. disease free survival (Time Frame - 46 month)

2. overall survival (Time Frame - 46 month)

Geprüfte Regime

  • Pembrolizumab:
    Pembrolizumab at fixed dose: 200 mg q3w i.v. for 2 cycles

Quelle: ClinicalTrials.gov


Das könnte Sie auch interessieren